The Source Blog
Recent Action in Pharmaceuticals
Introduced: 2023 Status: In Process
As introduced, prohibits a healthcare prescriber from issuing a prescription for a dual-purpose prescription medication for diabetes to a person in this state if the person does not have a diagnosis of diabetes; defines a …
SB 1314 (see companion bill HB 1419) – Tennessee
Introduced: 2023 Status: In Process
As introduced, prohibits a healthcare prescriber from issuing a prescription for a dual-purpose prescription medication for diabetes to a person in this state if the person does not have a diagnosis of diabetes; defines a …
HB 0282 (see companion bill SB 0869) – Tennessee
Introduced: 2023 Status: In Process
As introduced, authorizes as part of the practice of pharmacy the prescribing of dietary fluoride supplements, certain immunization agents, opioid antagonists, and certain other drugs and products; makes various other changes to pharmacy practice. – …
SB 0869 (see companion bill HB 0282) – Tennessee
Introduced: 2023 Status: In Process
As introduced, authorizes as part of the practice of pharmacy the prescribing of dietary fluoride supplements, certain immunization agents, opioid antagonists, and certain other drugs and products; makes various other changes to pharmacy practice. – …
HB 1754 (see companion bill SB 622) – Texas
Introduced: 2023 Status: Inactive / Dead
Relating to the disclosure of certain prescription drug information by a health benefit plan.
SB 622 (see companion bill HB 1754) – Texas
Introduced: 2023 Status: Enacted
Relating to the disclosure of certain prescription drug information by a health benefit plan.
HB 2021 (see companion bill SB 1137) – Texas
Introduced: 2023 Status: Inactive / Dead
Relating to applicability of certain insurance laws to pharmacy benefit managers.
Next | See all Legislation Records
District Court: District of Columbia Status: Pending
A complaint filed by Merck, a multinational pharmaceutical company, alleges that the drug price negotiation process detailed in the Inflation Reduction Act (IRA) violates the …
FTC v. Amgen Inc. & Horizon Therapeutics Plc. – Federal
District Court: Northern District of Illinois, Eastern Division Status: Pending
The FTC filed a lawsuit requesting a temporary restraining order and preliminary injunction to block Amgen Inc. from acquiring Horizon Therapeutics. Amgen agreed to purchase …
PhRMA v. Stolfi – Oregon
District Court: District Court of Oregon Status: Pending
PhRMA is challenging Oregon’s drug price transparency laws HB 4005, 2018 (Disclosure Law) and HB 2658, 2019 (Advance Notification Law) alleging that the laws are …
Pharmaceutical Care Management Association (PCMA) v. Mulready – Oklahoma
District Court: District Court of Western District of Oklahoma Status: Decided
The 2019 Oklahoma law, Patient’s Right to Pharmacy Choice Act, targets PBM conflict of interest by prohibiting higher reimbursement rates for PBM-owned pharmacies and bans …
State of Ohio v. OptumRx – Ohio
District Court: Ohio Court of Common Pleas (Franklin County) Status: Pending
On March 15, 2019, Ohio’s attorney general Dave Yost sued OptumRx in Ohio state court, claiming that between 2015 and 2018, the PBM failed to pass …
Minnesota v. Sanofi-Aventis U.S. LLC – Minnesota
District Court: District Court of New Jersey Status: Pending
Minnesota’s attorney general filed a suit accusing Sanofi, Eli Lilly, and Novo Nordisk, the three largest manufacturers of insulin, of price gouging. The lawsuit, filed in …
Pharm. Care Mgmt. Ass’n v. Tufte – North Dakota
District Court: District of North Dakota Status: Pending
Trade association representing pharmacy benefit managers (PBMs) brought action against North Dakota state officials in their official capacities, alleging that Employee Retirement Income Security Act …
Next | See all Litigation Records
News & Opinions
Articles & Reports
American Medical Association September 12, 2023
Business Group on Health August 22, 2023
NEJM July 8, 2023
Trends in Pharmaceuticals
State Pharmaceutical Legislation
Click on highlighted states to see all legislative action to regulate pharmaceutical price and competition in the 2019 session. Click to see 2018 trends for a side-by-side comparison.
2019 Drug Pricing Transparency Legislation
Pharmaceutical price transparency legislation requires disclosures from drug manufacturers and insurers to help lawmakers and the public better understand how drugs are priced and how those prices affect insurance premiums. Click to see 2018 trends for a side-by-side comparison.
-
Key:
- Enacted
- Considered
2019 Pharmaceutical Rate-Setting Legislation
Rate setting legislation either establishes the price of a prescription drug or sets the maximum amount a payer can pay for a drug. Click on highlighted states to see rate-setting legislation considered or enacted in the 2019 session. Click to see 2018 trends for a side-by-side comparison.
-
Key:
- Enacted
- Considered
2019 Drug Importation Legislation
Click on highlighted states to see drug importation legislation considered or enacted in the 2019 session. Click to see 2018 trends for a side-by-side comparison.
-
Key:
- Enacted
- Considered
2019 Drug Price Gouging Prohibition Legislation
Price gouging prohibitions typically empower the state Attorney General to act if the price of a drug is raised above a threshold. Click on highlighted states to see legislation considered in the 2019 session. Click to see 2018 trends for a side-by-side comparison.
-
Key:
- Enacted
- Considered
2019 Pharmacy Benefit Manager Regulation Legislation
Legislation to regulate Pharmacy Benefit Managers (PBMs) typically include provisions that 1) require PBMs to register with the state, 2) mandate disclosures by PBMs, or 3) prevent PBMs from incentivizing the use of mail-order pharmacies. Click to see 2018 trends for a side-by-side comparison.
-
Key:
- Enacted
- Considered